10-K: SI-BONE Enters New Manufacturing Agreement and Files 10-K Report

SI-BONE, a medical device company, has entered into a new manufacturing agreement with RMS Company and filed its annual 10-K report, detailing its financial performance and strategic initiatives.

Summary

• SI-BONE has entered into a new manufacturing and supply agreement with RMS Company, effective February 23, 2024, superseding their previous agreement from June 2021.
• The agreement ensures RMS will supply SI-BONE with products listed in Exhibits A through D, with SI-BONE purchasing 100% of its requirements from RMS unless otherwise specified.
• SI-BONE will provide a 12-month rolling forecast to RMS, updated quarterly, for capacity planning purposes only.
• The agreement outlines ordering procedures, lead times, delivery terms, and inspection processes, including a 60-day inspection period for non-conforming products.
• Payment terms are set at 45 days from the date of a valid invoice, with pricing detailed in Exhibits A-D.
• The agreement has an initial term of three years, automatically renewing for one-year periods unless terminated with 90 days' notice.
• SI-BONE's 10-K filing for the fiscal year ended December 31, 2023, reports a net loss of $43.3 million, with an accumulated deficit of $400.4 million.
• The company's total addressable market in the United States is estimated to exceed $3.0 billion, with significant opportunities in sacroiliac joint dysfunction, adult spinal deformity, and pelvic trauma.
• SI-BONE's iFuse implants are supported by over 125 publications and several large prospective clinical studies, demonstrating safety, effectiveness, and cost-effectiveness.
• The company markets its products through a direct sales force and third-party agents, targeting over 12,000 physicians in the U.S.
• SI-BONE has been issued 59 U.S. patents and has 34 pending U.S. patent applications, with key patents expiring between 2025 and 2039.
• The company is subject to extensive regulations by the FDA and other international regulatory bodies, and must comply with healthcare fraud and abuse laws.
• SI-BONE relies on third-party manufacturers for its products, with RMS Company being a key supplier for iFuse-3D and iFuse-TORQ implants.
• The company's human capital resources include 344 employees, with a focus on diversity, inclusion, and employee development.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects such as a new manufacturing agreement, strong clinical evidence, and a large addressable market, the company's significant losses, reliance on a single product family, and competitive pressures temper the overall sentiment. The company is in a growth phase, but faces significant challenges.

Positives

• The new manufacturing agreement with RMS Company provides a stable supply chain for SI-BONE's products.
• The company has a large addressable market with significant growth potential in various segments.
• Extensive clinical evidence supports the safety and effectiveness of SI-BONE's iFuse implants.
• The company has a strong intellectual property portfolio, protecting its technology and products.
• SI-BONE has a dedicated sales force and is actively expanding its reach to physicians and patients.
• The company is focused on innovation and has a pipeline of products in various stages of development.

Negatives

• SI-BONE has incurred significant operating losses since its inception and expects to continue incurring losses.
• The company is dependent on a limited number of third-party suppliers, which could pose a risk to its supply chain.
• The company faces intense competition in the medical device industry, which could impact its market share and pricing.
• The company is highly dependent on revenue from a single family of products focused on sacroiliac joint fusion.
• The company is subject to extensive governmental regulations, and failure to comply could cause its business to suffer.

Risks

• Prolonged inflation and supply chain disruptions could result in delayed product launches and decreased profit margins.
• Disruptions in the supply of materials and components could adversely affect the company's business.
• If healthcare payors reverse decisions to cover minimally invasive sacroiliac joint fusion exclusively when performed with iFuse triangular implants, the company's market share and average selling prices could decline.
• The company may not be able to convince physicians that its products are attractive alternatives to competitors' products.
• The company is dependent on a limited number of third-party suppliers, some of them single-source, for most of its products and components.
• The company and its sales representatives must comply with U.S. federal and state fraud and abuse laws, and failure to comply could negatively affect its business.
• Failure or perceived failure to comply with data privacy and security laws could harm the company's business.

Future Outlook

The company anticipates continuing to build products and pursue additional indications, with research and development expenses expected to increase in the future. The company also expects to continue to grow its specialized sales force to foster relationships with physicians and support revenue growth.

Industry Context

The announcement reflects the ongoing competition and innovation in the medical device industry, particularly in the area of musculoskeletal disorders. The new manufacturing agreement is a strategic move to secure supply and support growth, while the 10-K filing provides transparency into the company's financial health and market position. The company is competing with larger, more diversified companies, as well as smaller companies offering alternative treatments.

Comparison to Industry Standards

• SI-BONE's reliance on a single family of products is a risk compared to diversified medical device companies like Medtronic and Globus Medical, which offer a broader range of solutions.
• The company's focus on clinical evidence is a strength, differentiating it from competitors who may not have the same level of published data.
• The company's direct sales force is a significant investment, but it may be less efficient than the larger sales forces of competitors like Medtronic.
• The company's gross margin of 79% is relatively high, but it is facing pricing pressure from competitors and changes in reimbursement policies.
• The company's net loss of $43.3 million is a concern, but it is not uncommon for growth-stage medical device companies to operate at a loss while investing in research and development and commercialization.

Related Party Transactions

• The company has a joint development agreement with SeaSpine Orthopedics Corporation, a related party due to a common board member, Keith Valentine, who resigned from the board of Orthofix on October 4, 2023.

Stakeholder Impact

• Shareholders may be concerned about the company's ongoing losses and the potential impact on the stock price.
• Employees may benefit from the company's focus on diversity, inclusion, and employee development.
• Customers (physicians and hospitals) will benefit from the company's commitment to innovation and clinical evidence.
• Suppliers will benefit from the new manufacturing agreement, which provides a stable source of business.
• Creditors may be concerned about the company's debt levels and its ability to generate positive cash flow.

Next Steps

• SI-BONE will continue to develop new products and pursue additional indications.
• The company will continue to expand its sales force and marketing efforts.
• SI-BONE will continue to monitor and comply with regulatory requirements.
• The company will continue to invest in research and development to support its product pipeline.

Key Dates

Keywords

SI-BONE, iFuse, sacroiliac joint, spinal fusion, pelvic trauma, medical device, manufacturing agreement, 10-K report, clinical evidence, intellectual property, sales force, regulatory compliance